MeiraGTx | Company Profile
Contact Information
Industry & Market
Company Metrics
Funding Information
Headcount Distribution
By Department
Department Breakdown
Technology Stack
Analytics & Tracking
Development
Video & Media
Keywords & Focus Areas
MeiraGTx
Overview
MeiraGTx is a clinical-stage genetic medicines company founded in 2015. It specializes in developing gene therapies for severe inherited and acquired diseases, focusing on conditions with significant unmet medical needs, such as inherited eye diseases, Parkinson’s disease, and radiation-induced xerostomia. The company has a broad pipeline of gene therapy candidates, including four late-stage clinical programs.
It develops advanced viral vectors to ensure effective and safe delivery of therapeutic genes and operates five global manufacturing facilities, two of which are licensed for GMP viral vector production. A notable innovation is the riboswitch gene regulation platform, enabling precise in vivo control of gene expression, applied across therapies for metabolic peptides, cell therapies for cancer, and chronic pain. In 2025, a joint venture with Hologen was launched to advance gene therapies for Parkinson’s disease and obesity.
Collaboration with healthcare providers and research institutions enables the company to address rare genetic disorders and expand options for more common diseases, enhancing both manufacturing and clinical capabilities.
Basic Information
| Industry | Biotechnology |
|---|---|
| Founded | 2015 |
| Revenue | 34.5M |
| Headquarters | 92 York Street, London, England, W1H 1QX, United Kingdom |
| Alexa Ranking | 462396 |
Contact Details
- Phone: +1 646-490-2965
- Website: meiragtx.com
- LinkedIn: linkedin.com/company/meiragtx
Key Focus Areas & Initiatives
- Gene therapy for inherited and acquired diseases
- Development of advanced viral vectors
- Clinical-stage programs for eye diseases, Parkinson’s, and xerostomia
- Riboswitch gene regulation platform for precise gene expression control
- GMP viral vector manufacturing
- Joint venture with Hologen for gene therapies in Parkinson’s disease and obesity
- Collaboration with healthcare providers and research institutions
- Expanding treatment options for rare and common diseases
Technologies Used
- AT Internet
- Bootstrap Framework
- Google Analytics
- Google Cloud Hosting
- Google Font API
- Google Tag Manager
- Microsoft Office 365
- Mobile Friendly
- New Relic
- Nginx
- Typekit
- Vimeo
- WordPress.org
- YouTube
Community
